Onimode Yetunde Ajoke, Dairo David Magbagbeola, Ellmann Annare
Nuclear Medicine Unit, Department of Radiation Oncology, College of Medicine, Faculty of Clinical Sciences, University of Ibadan, Oyo State, Nigeria.
Nuclear Medicine Centre, University College Hospital, Ibadan, Oyo State, Nigeria.
Pan Afr Med J. 2018 Jan 18;29:48. doi: 10.11604/pamj.2018.29.48.13655. eCollection 2018.
Typically hyperthyroidism has been more often associated with the female gender. There is a large female predilection (male:female sex ratio up to 1:10), with little documentation in the literature about wholly male hyperthyroid populations. A male incidence of 0.7 per 100, 000 has been reported for South African men while the women have a relatively higher rate of 0.02. There is no documented evidence between male and female genders in response to treatment of PH with radioactive iodine (RAI), although operational evidence suggests that hyperthyroidism in males is less amenable to RAI treatment (RAIT) than females. This study therefore proposed to evaluate male hyperthyroid patients with Graves' disease (GD) treated at our facility, for factors affecting outcome of RAIT.
This is a retrospective analysis of records of hyperthyroid patients who were treated with RAI over a 19-year period at a university teaching hospital, in the Western Cape of South Africa.
The overall cure rate was 76.4% for these male patients. Cure was observed as euthyroidism in 31 patients (15.3%) and hypothyroidism in 129 (63.5%). Age, thyroid uptake, severity of hyperthyroidism, previous antithyroid drug (ATD) usage, administered quantity of RAI, ethnicity and patients' pulse at presentation were not significant in influencing outcome.
Factors which have been evaluated as affecting outcome of RAIT were unimportant in these patients. Despite the mainly hyperthyroid presentation of the patients, RAIT was so effective that the main type of cure after therapy was hypothyroidism.
通常,甲状腺功能亢进症在女性中更为常见。女性患病率很高(男女比例高达1:10),而关于完全男性甲状腺功能亢进人群的文献记载很少。据报道,南非男性甲状腺功能亢进症的发病率为每10万人中有0.7例,而女性的发病率相对较高,为0.02。虽然实际证据表明男性甲状腺功能亢进症比女性更难通过放射性碘(RAI)治疗,但尚无文献证明男女在放射性碘治疗毒性弥漫性甲状腺肿(PH)的反应方面存在差异。因此,本研究旨在评估在我们机构接受治疗的男性毒性弥漫性甲状腺肿(GD)患者放射性碘治疗(RAIT)的疗效影响因素。
这是一项对南非西开普省一家大学教学医院19年间接受RAI治疗的甲状腺功能亢进患者记录的回顾性分析。
这些男性患者的总体治愈率为76.4%。治愈表现为甲状腺功能正常的有31例(15.3%),甲状腺功能减退的有129例(63.5%)。年龄、甲状腺摄取率、甲状腺功能亢进的严重程度、既往抗甲状腺药物(ATD)使用情况、RAI给药量、种族和就诊时患者的脉搏对疗效无显著影响。
在这些患者中,已评估的影响RAIT疗效的因素并不重要。尽管患者主要表现为甲状腺功能亢进,但RAIT非常有效,治疗后主要的治愈类型是甲状腺功能减退。